ASH Clinical News Hematology Pipeline Update | Page 3
FEBRUARY 2015
AMERICAN SOCIETY OF HEMATOLOGY
HEADQUARTERS
r International Inc. 2021 L Street NW, Suite 900
oration. All rights reserved. USBS/MG114/14-0049
Washington, DC 20036
www.hematology.org
Tel: 202-776-0544
EDITOR-IN-CHIEF
Mikkael Sekeres, MD, MS
Vice-Chair for Clinical Research
Director, Leukemia Program
Cleveland Clinic, Taussig Cancer Institute
Cleveland, OH
ASSOCIATE EDITORS
Beth Faiman, CNP, PhD
Cleveland Clinic
Cleveland, OH
Hematology Pipeline Update:
Newly Approved Drugs
The 2014 ASH Annual Meeting included a
first-of-its-kind Special Education Session
on Newly Approved Drugs – an extension
of the Society’s ASH/FDA webinar series on
agents recently approved by the U.S. Food
and Drug Administration.
In each didactic presentation, physicians
discussed hematologic drugs approved in
2014, in the areas of hemophilia, chronic
lymphocytic leukemia (CLL), and mantle cell
lymphoma.
•
•
Alice Ma, MD
University of North Carolina School of Medicine
Chapel Hill, NC
David Steensma, MD
Dana-Farber Cancer Institute
Boston, MA
Keith Stewart, MBChB, MBA
Mayo Clinic
Scottsdale, AZ
PUBLISHER
American Medical Communications
EDITORIAL
approval to treat patients with CLL
who carry a deletion in chromosome
17 (17p deletion) in July 2014. Ibrutinib received a breakthrough therapy
designation for this use. Ibrutinib
also received accelerated approval in
November 2013 for the treatment of
patients with mantle cell lymphoma
who have received at least one prior
therapy.
•
Margaret V. Ragni, MD, MPH, discussed new longer-lasting fusion
protein therapies, recombinant coagulation factor VIII (FVIII) Fc fusion protein
for hemophilia A and recombinant
coagulation factor IX (FIX) Fc fusion
protein for hemophilia B. Each agent
represents options for less-frequent
dosing regimens by improving on the
half-life of its non-fusion protein counterpart: 19 hours with rFVIIIFc (vs. 12.4
hours with rFVIII) and 82 hours with
rFIXFc (vs. 33.8 hours with rFIX).
Mitchell Smith, MD, PhD, discussed
ibrutinib which received expanded
Steven Coutre, MD, discussed idelalisib
which was approved in July 2014 for
the treatment of patients with relapsed
follicular B-cell non-Hodgkin lymphoma (FL), relapsed small lymphocytic
lymphoma (SLL), and relapsed CLL, in
combination with rituximab.
Each speaker focused on the issues clinicians face in treating patients with the new
drugs, including: appropriate population,
dosing, side effects, adverse events, drug/
drug interactions, and off-label use.
This supplement features clinical
research updates on each of these newly
approved drugs, as well as hematologic
drugs coming down the pipeline.
MANAGING EDITORS
Ariel Jones, AMC
Karen Learner, ASH
ART DIRECTOR
Ari Mihos
ASSISTANT ART DIRECTOR
Charlene DePrizio
DIGITAL PROJECTS MANAGER
Chris Gedikli
ADVERTISING
ACCOUNT MANAGER
Nick Luciano
[email protected]
Gene Conselyea
[email protected]
Recruitment advertising orders can be sent to:
DIRECTOR, RECRUITMENT CLASSIFIEDS
John Baltazar, CSMR
[email protected]
©2015 by the American Society of Hematology.
All materials contained in this newsletter are
protected by copyright laws and may not be
used, reproduced, or otherwise exploited in any
manner without the express prior written permission of ASH Clinical News. Any third-party
materials communicated to ASH Clinical News
become its copyrighted property and may be
used, reproduced, or otherwise exploited by
ASH Clinical News.
ASHClinicalNews.org
CONTENTS
FEATURES
2 Bleeding Disorders
5 Lymphoma
8 Leukemia
15 Myeloma
Subscription inquiries should be sent to: [email protected]
All correspondence for the American Society of Hematology should be sent to: American Society of Hematology,
2021 L Street NW, Suite 900, Washington DC 20036.
Neither the American Society of Hematology nor the publisher is responsible for statements made by any contributor. Statements or opinions expressed in ASH Clinical News magazine do not represent official policy of the American
Society of Hematology unless so stated. No responsibility is assumed by the American Society of Hematology or the
Publisher for any injury or damage to persons or property as a matter of product liability, negligence or otherwise or
from any use or operation of any methods, products, instructions or ideas contained in the material herein.
Although all advertising material published in ASH Clinical News magazine is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement by the American Society
of Hematology or the Publisher of the quality or value of such product or of the claim made of it by its manufacturer.
About the American Society of Hematology
The American S